行情

BLRX

BLRX

BioLine RX
NASDAQ

实时行情|Nasdaq Last Sale

2.500
+0.030
+1.21%
盘前: 2.550 +0.05 +2.00% 08:33 11/13 EST
开盘
2.420
昨收
2.470
最高
2.550
最低
2.340
成交量
6.30万
成交额
--
52周最高
13.05
52周最低
2.320
市值
2,450.33万
市盈率(TTM)
-0.0576
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLRX 新闻

  • BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.1天前
  • BioLineRx up 2% premarket on Q3 results
  • Seeking Alpha - Article.2天前
  • BioLine Rx Q3 EPS $(0.03) Beats $(0.64) Estimate
  • Benzinga.2天前
  • BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update
  • PR Newswire.2天前

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

BLRX 简况

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.
展开

Webull提供BioLineRX Ltd.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。